Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

354 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

1,903 enrolled

Breast

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

Phase 2 Recruiting

375 enrolled

Breast

Breast Neoplasms

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Phase 2 Recruiting

88 enrolled

Breast

Breast Neoplasms

NCT07190443 2025-09-29

AURA

Phase 3 Recruiting

290 enrolled

Breast

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

Phase 3 Recruiting

220 enrolled

Breast

Breast Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Phase 2 Recruiting

50 enrolled

Breast

Breast Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

5,500 enrolled

Breast

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

Phase 2 Recruiting

90 enrolled

Breast

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast

Breast Neoplasms

NCT05780567 2023-04-21

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Phase 3 Recruiting

1,946 enrolled

Breast

Breast Neoplasms

NCT04666961 2022-04-22

HORNEO01

Phase 2 Recruiting

262 enrolled

Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Clinical Trials

ELEGANCE

OPERA-01

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

DEBRA

PIKALO-1

POWER II

IMPULSE

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

ADEPT

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

AURA

TREAT ctDNA

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

CAMBRIA-2

CAMERAN

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

HORNEO01